Article
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
EBioMedicine - 1 Feb 2020
Engelberts Patrick J, Hiemstra Ida H, de Jong Bart, Schuurhuis Danita H, Meesters Joyce, Beltran Hernandez Irati, Oostindie Simone C, Neijssen Joost, van den Brink Edward N, Horbach G Jean, Verploegen Sandra, Labrijn Aran F, Salcedo Theodora, Schuurman Janine, Parren Paul W H I, Breij Esther C W
Abstract excerpt
BACKGROUND: DuoBody®-CD3xCD20 (GEN3013) is a full-length human IgG1 bispecific antibody (bsAb) recognizing CD3 and CD20, generated by controlled Fab-arm exchange. Its Fc domain was silenced by introduction of mutations L234F L235E D265A. METHODS: T-cell activation and T-cell-mediated cytotoxicity were measured by flow cytometry following co-culture with tumour cells. Anti-tumour activity of DuoBody-CD3xCD20 was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.